Collaborative Arrangements and Acquisitions (Tables)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of collaborative arrangement activity net loss attributable to noncontrolling interest

An aggregate summary of net income attributable to noncontrolling interest related to the Company’s VIEs for the three and nine months ended September 30, 2017 and 2016 is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(in thousands)
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments	$	238,946		$	2,406		$	222,448		$	6,080
(Benefit from) provision for income taxes	(120,181		)	(510		)	(111,658		)	20,063
Decrease (increase) in fair value of contingent payments	69,550			(1,200		)	62,560			(59,350		)
Net loss (income) attributable to noncontrolling interest	$	188,315		$	696		$	173,350		$	(33,207	)

Changes in fair value of contingent payments

During the three and nine months ended September 30, 2017 and 2016, the (increases) decreases in the fair value of the contingent payments related to the Company’s VIEs were as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2017		2016			2017			2016
	(in thousands)
Parion	$	69,550	$	(1,100	)	$	63,460		$	(58,500	)
BioAxone	—		(100		)	(900		)	(850		)

Schedule of fair value of contingent payments

The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table:

	September 30, 2017		December 31, 2016
	(in thousands)
Parion	$	—	$	238,800
BioAxone	18,900		18,000

Schedule of collaborative arrangement summary of items related to variable interest entities

The table below summarizes items related to the Company’s VIEs included in the Company’s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.

	September 30, 2017		December 31, 2016
	(in thousands)
Restricted cash and cash equivalents (VIE)	$	1,803	$	47,762
Prepaid expenses and other current assets	42		6,812
Intangible assets	29,000		284,340
Other assets	280		399
Accounts payable	455		415
Accrued expenses	1,021		1,330
Other liabilities, current portion	119		2,137
Deferred tax liability	8,338		131,446
Other liabilities, excluding current portion	—		300
Noncontrolling interest	12,167		181,609